Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
205.71
-0.20 (-0.10%)
At close: Oct 29, 2025, 4:00 PM EDT
200.02
-5.69 (-2.77%)
After-hours: Oct 29, 2025, 4:10 PM EDT
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 158.05M EUR in the quarter ending June 30, 2025, with 339.04% growth. This brings the company's revenue in the last twelve months to 490.75M, up 54.50% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
490.75M EUR
Revenue Growth
+54.50%
P/S Ratio
21.22
Revenue / Employee
482,544 EUR
Employees
1,017
Market Cap
12.57B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ASND News
- 21 days ago - Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia - GlobeNewsWire
- 2 months ago - Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 - GlobeNewsWire
- 2 months ago - Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference - GlobeNewsWire
- 2 months ago - Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Ascendis Pharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - GlobeNewsWire
- 3 months ago - FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 3 months ago - New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life - GlobeNewsWire